Skip to content

Study · Randomized controlled trial · n = 15 · 2019

8 results

Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.

Jones KL, Rigda RS, Buttfield MDM, Hatzinikolas S, Pham HT, Marathe CS, Wu T, Lange K, Trahair LG, Rayner CK, Horowitz M

Diabetes, obesity & metabolism14 Feb 2019Cited by 57 (Europe PMC)

PMID30623563 (opens in a new tab)DOI10.1111/dom.13633 (opens in a new tab)PepBankPUB-30623563
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy participants, lixisenatide slowed gastric emptying versus placebo, measured by retention at 120 minutes (P < 0.01).

    In plain wordsLixisenatide slowed gastric emptying versus placebo in healthy participants.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying in healthy participants
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Measurements

    P value (gastric retention at 120 min)
    < 0.01 P
    lixisenatide vs placebo

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with diabetes, lixisenatide slowed gastric emptying versus placebo, measured by retention at 120 minutes (P < 0.01).

    In plain wordsLixisenatide slowed gastric emptying versus placebo in participants with diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying in diabetes
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Measurements

    P value (gastric retention at 120 min)
    < 0.01 P
    lixisenatide vs placebo

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy participants, lixisenatide attenuated the rise in SMA flow versus placebo (P < 0.01).

    In plain wordsLixisenatide reduced the rise in intestinal artery blood flow versus placebo in healthy participants.

    Peptide
    Lixisenatide
    Outcome
    DecreaseSMA flow rise in healthy participants
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Measurements

    P value (SMA flow rise)
    < 0.01 P
    lixisenatide vs placebo

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In participants with diabetes, lixisenatide attenuated the rise in SMA flow versus placebo (P < 0.01).

    In plain wordsLixisenatide reduced the rise in intestinal artery blood flow versus placebo in participants with diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseSMA flow rise in diabetes
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy participants, lixisenatide attenuated the decrease in systolic BP versus placebo (AUC 0-120 minutes, P < 0.001).

    In plain wordsLixisenatide reduced the fall in systolic blood pressure versus placebo in healthy participants.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSystolic blood pressure in healthy participants
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In participants with diabetes, lixisenatide attenuated the decrease in systolic BP versus placebo (AUC 0-120 minutes, P < 0.001).

    In plain wordsLixisenatide reduced the fall in systolic blood pressure versus placebo in participants with diabetes.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSystolic blood pressure in diabetes
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM.
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy participants, lixisenatide reduced glucose incremental AUC versus placebo (0-120 minutes, P < 0.001).

    In plain wordsLixisenatide reduced the rise in glucose versus placebo in healthy participants.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucose incremental AUC in healthy participants
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Plasma glucose (incremental AUC 0-120 minutes) was greater in participants with T2DM (P < 0.005) than in healthy participants, and lower after lixisenatide in both groups (P < 0.001).
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In participants with diabetes, lixisenatide reduced glucose incremental AUC versus placebo (0-120 minutes, P < 0.001).

    In plain wordsLixisenatide reduced the rise in glucose versus placebo in participants with diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucose incremental AUC in diabetes
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Plasma glucose (incremental AUC 0-120 minutes) was greater in participants with T2DM (P < 0.005) than in healthy participants, and lower after lixisenatide in both groups (P < 0.001).
    2 context sentences
    Summary · context
    Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.
    Summary · context
    All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.